Test Price
2,800 AED✅ Home Collection Available
SCN5A Gene Brugada Syndrome Type 1 Genetic Test in UAE
Executive Summary & Core Metrics
99.9% Diagnostic Sensitivity via ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) NGS platform for full SCN5A gene sequencing.
Premium Logistics: VIP Mobile Phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM across all UAE emirates.
Clinical Guidance: Complimentary post-test teleconsultation with a Consultant Medical Geneticist for result interpretation and risk stratification.
Insurance & Billing: Direct billing verification via WhatsApp +971 54 548 8731 with major UAE health insurers.
UAE Regulatory Compliance: Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Test Overview & Methodology
This advanced genetic test sequences the entire SCN5A gene using Next Generation Sequencing (NGS) to detect pathogenic and likely pathogenic variants associated with Brugada syndrome type 1. This life-threatening cardiac channelopathy predisposes individuals to ventricular arrhythmias and sudden cardiac death. Full intron-exon boundary coverage ensures detection of deep intronic variants and copy number alterations missed by conventional Sanger panels. Results guide implantable cardioverter-defibrillator (ICD) candidacy, family cascade screening, and lifestyle modification strategies.
| Feature | Our NGS Test | Closest Alternative (Sanger Panel) |
|---|---|---|
| Method | NGS (full gene and intron-exon boundaries) | Sanger sequencing of selected exons |
| Sensitivity | >99.9% (includes deep intronic variants) | ~95% (misses regulatory and intronic regions) |
| Turnaround Time | 3-4 Weeks | 6-8 Weeks |
| Price | 2,800 AED | 2,500 - 3,000 AED |
| Clinical Report | ACMG-classified variants with actionable management guidance | Limited variant interpretation |
Physician Insight & Safety Protocols
"A positive SCN5A variant identified through NGS provides a molecular diagnosis of Brugada syndrome type 1 in the appropriate clinical context. This finding must be integrated with ECG phenotype, sodium channel blockade challenge results, and family history. A negative result does not exclude the syndrome, as phenocopies and non-genetic causes exist. All patients should receive post-test genetic counseling and ongoing rhythm surveillance. Treatment decisions, including ICD implantation, must be made by the managing cardiologist based on the complete clinical picture."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Clinical Advisory
Genetic test results should always be interpreted by a qualified medical geneticist or cardiologist experienced in cardiac channelopathies. Do not alter any prescribed medication, including antiarrhythmic agents, without direct consultation with your treating physician. Abrupt discontinuation of cardiac therapy may provoke arrhythmic events.
Exclusion Criteria
- Active febrile illness: may transiently alter ECG phenotype and confound genotype-phenotype correlation.
- Pregnancy: requires prior genetic counselling to discuss implications for the fetus and maternal management.
- Minors: parental or guardian consent mandatory under UAE Federal Law No. 2 of 2019 and PDPL regulations governing pediatric genetic testing.
Emergency Red Flags: Seek immediate medical attention for syncope, nocturnal agonal respiration, witnessed sudden cardiac arrest, or strong family history of sudden cardiac death under 45 years.
Patient FAQ & Clinical Guidance
1. What does a positive SCN5A mutation mean for my heart health?
A pathogenic variant in the SCN5A gene indicates a significantly elevated risk for Brugada syndrome type 1, a cardiac channelopathy that can lead to ventricular arrhythmias and sudden cardiac death. This result should prompt comprehensive cardiac evaluation including ECG, Holter monitoring, and family cascade screening. Your managing cardiologist will determine the appropriate risk mitigation strategy, which may include lifestyle modifications and consideration of an implantable cardioverter-defibrillator (ICD).
2. How accurate is this NGS test for Brugada syndrome compared to traditional methods?
Our NGS platform achieves greater than 99.9% analytical sensitivity with full coverage of all exons, intron-exon boundaries, and deep intronic regions. This significantly outperforms conventional Sanger sequencing, which typically covers only selected exons and misses regulatory variants and copy number alterations responsible for up to 10-15% of Brugada syndrome cases.
3. Can I have the blood sample collected at home in the UAE?
Yes, our ISO-certified mobile phlebotomy service operates daily from 8 AM to 11 PM across all seven emirates. A trained nurse collects whole blood in EDTA tubes using sterile technique, with temperature-controlled cold-chain transport to our Dubai Healthcare City laboratory ensuring sample integrity from your doorstep.
4. How long does it take to receive my results?
The standard turnaround time is 3 to 4 weeks from sample receipt at our laboratory. This accounts for DNA extraction, library preparation, NGS sequencing, bioinformatic analysis, variant classification per ACMG guidelines, and clinical report generation by our Consultant Medical Geneticist.
5. Will my insurance cover this test?
Many UAE health insurers provide coverage for diagnostic genetic testing when ordered by a specialist. We offer direct billing verification via WhatsApp at +971 54 548 8731. Pre-authorization may be required; our billing team will assist you with the process.
UAE Regulatory & Data Privacy Adherence
This genetic test is performed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), ensuring your genetic data is encrypted, access-controlled, and never shared without explicit consent. All clinical operations adhere to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, governing telemedicine and digital health records. Patient safety and informed consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE is licensed by the Dubai Health Authority (DHA) under Facility License Number 1143, operating from Premises 105, Floor 1, Building 33, Dubai Healthcare City.
Clinical & Logistical Metadata
| Test Name | SCN5A Gene Brugada Syndrome Type 1 Genetic Test (NGS Full Sequencing) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3-4 Weeks |
| Sample Type / Matrix | Whole blood (EDTA tube), extracted genomic DNA, or FTA card blood spot |
| Methodology Used | Next Generation Sequencing (NGS) with full intron-exon boundary coverage |
| ICD-10-CM Code | I49.81 (Brugada syndrome) |
| LOINC Code | 94437-2 (SCN5A gene full sequencing analysis in blood) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians